Resources

Publications

Filter Publications

Product



Year

Alterations in Liver Perfusion in Adults with Fontan Circulation as Assessed by Dual Cholate Clearance

Yuli Y. Kim, Annique Nyman, Yuan-Shung Huang, Alexis Z. Tomlinson, Michael P. McRae, Greg T. Everson, Sumeet Vaikunth, Benjamin Rosenthal, Jack Rychik, Maarouf A. Hoteit | Journal of the American Heart Association | 2025 | March 2025

HepQuant SHUNT

March 2025

Rencofilstat Treatment Improves Liver Function in MASH With Advanced Fibrosis as Quantified by HepQuant DuO

Stephen A. Harrison, Patrick Mayo, Todd Hobbs, Caroline Zhao, Carlos Canizares, Robert Foster, Michael P. McRae, Steve M. Helmke, Gregory T. Everson | Liver International | 01 March 2025

HepQuant DuO, HepQuant SHUNT

November 2024

Measuring the Risk of Clinical Events (RISK ACE) by Quantifying Liver Function: A Patient-Centric Model

John Kittelson, Michael P. McRae, Gregory T. Everson | European Journal of Internal Medicine 2024; 132:160-163 | 29 November 2024

HepQuant DuO, HepQuant SHUNT

Cost-Effectiveness of an Oral Cholate Challenge Test for the Management of Patients at Risk for Large Esophageal Varices

Shailesh Chavan, Michael P. McRae, Kelly R. Pitts, Gregory T. Everson | Research Article | published 22 November 2024 PLOS ONE

HepQuant DuO, HepQuant SHUNT

Cholate Shunt, Oral Cholate Challenge and Endoscopic Lesions of Portal Hypertension: The SHUNT-V Study.

Mitchell Shiffman, K. Rajender Reddy, Michael, D. Leise3, Kamran Qureshi, Alastair D. Smith, Steve Helmke, John Kittelson, Michael P. McRae, Joanne C. Imperial, Gregory T. Everson, the SHUNT-V Investigators | Alimentary Pharmacology & Therapeutics, 2024; 61: 75-87

HepQuant DuO, HepQuant SHUNT

Scientific Research: Posters & Presentations

February 2023

Fourth Annual HCC-TAG Conference

Huntington Beach, CA

November 2022

Obesity & NASH Drug Development Summit

Boston, MA

November 2022

AASLD – The Liver Meeting 2022

Poster of Distinction: The Oral Cholate Challenge Test Defines Likelihood of Large Esophageal Varices in an Overweight and Obese US Population 

Maintenance Therapy with GLP-1 Receptor Agonists Does Not Impact the​ Clearance of Orally Administered Isotopes of Unconjugated Cholate

Cost-Effectiveness of the HepQuant DuO Test for the Management of Patients at Risk for Large Esophageal Varices

Poster of Distinction: Pilot Study of a Model Based on Noninvasive Assessments of Portal-Systemic Shunting (HepQuant DuO) 

Poster of Distinction: Resmetirom Therapy of MASH-Associated Child Pugh A Cirrhosis Reduces Estimated Risk for Clinical Outcome Based on HepQuant RISK ACE Model  

The Oral Cholate Challenge Test Identifies the MASH Patients with ≥F3 Fibrosis with Greatest Hepatic Impairment Who Show the Most Benefit from Short-term Rencofilstat Therapy

SEE ALL